Call us today: +1 (304) 470-2225
You can use WPML or Polylang and their language switchers in this area.

Business Insights

Mellalta Meets How Nanobiotix's Breakthrough NBTXR3 is Poised to Radically Transform the LA-HNSCC Landscape

How Nanobiotix’s Breakthrough NBTXR3 is Poised to Radically Transform the LA-HNSCC Landscape?

Locally Advanced Head and neck Cancer (LA-HNSCC) represents a significant clinical challenge. The standard of care (SOC) typically involves a combination of surgery, chemotherapy, and radiation therapy. However, there are significant limitations associated with these […]

Read More
Mellalta Meets: Xevinapant Takes the Lead in LA-HNSCC

Xevinapant Takes the Lead: Merck’s Bold Market Strategies to Outshine Rivals in LA-HNSCC !

For patients with unresected Locally Advanced Head & Neck Cancer (LA-SCCHN) who cannot undergo surgical resection, the current standard of care is high-dose cisplatin-based CRT which has shown to improve locoregional control, PFS and OS compared […]

Read More
Obesity and NASH Lilly’s Retatrutide Mellalta Meets

What KOLs Revealed? Lilly’s Retatrutide as an Emerging Treatment Choice in NASH & Obesity

The domain of Non-alcoholic steatohepatitis (NASH) and Obesity treatment is continually evolving, with new discoveries and insights that are reshaping our understanding of how to best combat this liver disease. One of the most talked-about […]

Read More
Gastrointestinal Flexible Endoscopes with AI, Robotics, and Augmented Reality

Innovative Advancements in GastroIntestinal (GI) Endoscopy: A New Era with AI, Robotics, and Augmented Reality

In the realm of Gastrointestinal Endoscopy, as the medical field advances, the integration of state-of-the-art technology is inevitable. Endoscopy has been a mainstay for both diagnostic and therapeutic interventions in gastroenterology. The introduction of AI, […]

Read More
Watch 2023 Actinium Pioneering Strategies_Mellalta Meets

Revealed: Actinium KOLs Engagement and Pioneering Strategies for Iomab-B and Actimab-A

As Actinium forges ahead with its transformative therapies, including Iomab-B and Actimab-A, its strategic approach extends beyond clinical trials and regulatory milestones. Actinium’s presentation of six abstracts at the Society for Nuclear Medicine and Molecular […]

Read More
Humira-Competitive-Landscape-June-2023 Implications of the AVT02 (Humira Biosimilar) by Teva and Alvotech on the Humira Biosimilar Market

Implications of the AVT02 (Humira Biosimilar) by Teva and Alvotech on the Humira Biosimilar Market

The pending second Biologics License Application (BsUFA) for AVT02 (Humira biosimilar) by Teva and Alvotech, on June 28th, 2023 (Today), could dramatically alter the dynamics within the Humira biosimilar market. Anticipated approval of AVT02 by […]

Read More
IDHI Mutation AML

How Acute myeloid leukaemia (AML) Clinical Landscape is transforming for IDH1 or IDH2 mutated patients? Key comments from ASH 2022

Acute myeloid leukaemia is a genetically heterogeneous hematologic malignancy in which approximately 8% and 12% of acute myeloid leukemias harbour an IDH1 or IDH2 mutation, respectively.  A generally inferior outcome is seen with IDH1 mutations […]

Read More